<div class="pk-crumbs" data-crumbs="[{&quot;label&quot;:&quot;Drugs&quot;,&quot;href&quot;:&quot;README.md&quot;},{&quot;label&quot;:&quot;A07A&quot;,&quot;href&quot;:&quot;atc/A07A.md&quot;},{&quot;label&quot;:&quot;vancomycin&quot;}]"></div>
<div class="pk-recnav" data-items="[{&quot;id&quot;:&quot;Vancomycin_Goyal2022_final_pk_model&quot;,&quot;label&quot;:&quot;Goyal_2022_final_pk_model&quot;,&quot;group&quot;:&quot;popPK&quot;,&quot;href&quot;:&quot;drugs/drug_vancomycin/Vancomycin_Goyal2022_final_pk_model.md&quot;,&quot;status&quot;:&quot;extracted \u00b7 stale&quot;,&quot;css&quot;:&quot;pk-badge--green&quot;,&quot;here&quot;:false},{&quot;id&quot;:&quot;Vancomycin_Goyal2022_population_typical_value&quot;,&quot;label&quot;:&quot;Goyal_2022_population_typical_value&quot;,&quot;group&quot;:&quot;popPK&quot;,&quot;href&quot;:&quot;drugs/drug_vancomycin/Vancomycin_Goyal2022_population_typical_value.md&quot;,&quot;status&quot;:&quot;extracted \u00b7 stale&quot;,&quot;css&quot;:&quot;pk-badge--green&quot;,&quot;here&quot;:false},{&quot;id&quot;:&quot;Vancomycin_Yoon2023_reference&quot;,&quot;label&quot;:&quot;Yoon_2023_reference&quot;,&quot;group&quot;:&quot;popPK&quot;,&quot;href&quot;:&quot;drugs/drug_vancomycin/Vancomycin_Yoon2023_reference.md&quot;,&quot;status&quot;:&quot;extracted \u00b7 stale&quot;,&quot;css&quot;:&quot;pk-badge--green&quot;,&quot;here&quot;:false},{&quot;id&quot;:&quot;pd_Vera_Yunca_2025_cfu&quot;,&quot;label&quot;:&quot;Vera-Yunca_2025 \u00b7 cfu&quot;,&quot;group&quot;:&quot;PD&quot;,&quot;href&quot;:&quot;drugs/drug_vancomycin/pd_Vera_Yunca_2025_cfu.md&quot;,&quot;status&quot;:&quot;rejected&quot;,&quot;css&quot;:&quot;pk-badge--red&quot;,&quot;here&quot;:false}]"></div>

# vancomycin

- **generic name:** vancomycin
- **ATC codes:** `A07AA09`, `J01XA01`, `S01AA28`
- **DrugBank:** [DB00512](https://go.drugbank.com/drugs/DB00512) · **PubChem:** [CID 14969](https://pubchem.ncbi.nlm.nih.gov/compound/14969)
- **molar mass:** 1449.254 g/mol (C66H75Cl2N9O24) — DrugBank
- **groups:** approved, investigational

## About

Vancomycin is a glycopeptide antibiotic used to treat serious bacterial infections, including staphylococcal infections, pneumonia, infective endocarditis, and pseudomembranous colitis. It is an approved medicine and appears on the WHO list of essential medicines, so it is widely used, typically in hospital settings for severe infections.

<small>Summary written by `glm-5.3-flash` from [Wikidata Q424027](https://www.wikidata.org/wiki/Q424027) and the WHO ATC classification; not checked by a person.</small>

## Molecules and molar masses

> The molar mass each model uses to convert mass to molar concentration and to form a metabolite molecule for molecule. Looked up, never estimated: DrugBank for the drug, the paper's own value or the PubChem entry matched to the paper's name for a metabolite.

| molecule | role | molar mass (g/mol) | formula | source | PubChem | records |
|---|---|---|---|---|---|---|
| vancomycin | parent | 1449.25 | C66H75Cl2N9O24 | DrugBank | [14969](https://pubchem.ncbi.nlm.nih.gov/compound/14969) | Goyal_2022, Yoon_2023 |

## Extraction summary

| extracted at | time | popPK e/r/o | PD e/r/o (paper) | PGx e/r/o | tokens in/out | LLM | papers | GROBID/JATS | OA/non-OA | NONMEM |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-10-04 18:56 | 16:04 | 3/0/0 | 1/0/0 | 1/0/0 | 357,902/36,434 | ollama / qwen3.8:27b-mtp-q8_0 | 23 | 1/22 | 23/0 | 0 |

## popPK records

| status | detail | model | model structure | params | citation | doi |
|---|---|---|---|---|---|---|
| <span class="pk-badge pk-badge--green">extracted</span> <span class="pk-badge pk-badge--stale">stale</span> <span class="pk-badge pk-badge--red" title="re-read by gpt-oss:120b (not confirmed, agreement 0.6). The first reading is what the record holds.">cross-check: disputed</span><br><sub>caveat: the record defines covariate effects (weight on clearance, renal function …) but the engineer simulated only…</sub><br><sub>STALE — current validate: extracted</sub><br><sub>route_to: `engineer_replication`</sub> | [Goyal_2022_final_pk_model](drugs/drug_vancomycin/Vancomycin_Goyal2022_final_pk_model.md) | ▶ model + simulator | 2-compartment, IV | 4 | Goyal RK et al., Population Pharmacokinetics of Vancomyc…, Frontiers in pharmacology (2022) | [10.3389/fphar.2022.873439](https://doi.org/10.3389/fphar.2022.873439) |
| <span class="pk-badge pk-badge--green">extracted</span> <span class="pk-badge pk-badge--stale">stale</span> <span class="pk-badge pk-badge--red" title="re-read by gpt-oss:120b (not confirmed, agreement 0.75). The first reading is what the record holds.">cross-check: disputed</span><br><sub>STALE — current validate: extracted</sub><br><sub>route_to: `engineer_replication`</sub> | [Goyal_2022_population_typical_value](drugs/drug_vancomycin/Vancomycin_Goyal2022_population_typical_value.md) | ▶ model + simulator | 2-compartment, IV | 4 | Goyal RK et al., Population Pharmacokinetics of Vancomyc…, Frontiers in pharmacology (2022) | [10.3389/fphar.2022.873439](https://doi.org/10.3389/fphar.2022.873439) |
| <span class="pk-badge pk-badge--green">extracted</span> <span class="pk-badge pk-badge--stale">stale</span> <span class="pk-badge pk-badge--orange" title="re-read by gpt-oss:120b (partly confirmed, agreement 0.944). The first reading is what the record holds.">cross-check: partial</span><br><sub>STALE — current validate: extracted</sub><br><sub>route_to: `engineer_replication`</sub> | [Yoon_2023_reference](drugs/drug_vancomycin/Vancomycin_Yoon2023_reference.md) | ▶ model + simulator | 2-compartment, IV | 5 | Yoon S et al., Model-informed precision dosing in vanc…, Frontiers in pharmacology (2023) | [10.3389/fphar.2023.1252757](https://doi.org/10.3389/fphar.2023.1252757) |

## Pharmacodynamics (PD)

| status | detail | about | model | citation | doi |
|---|---|---|---|---|---|
| <span class="pk-badge pk-badge--green">extracted</span> <span class="pk-badge pk-badge--species" title="Animal study (mouse), not measured in people (from an LLM reading of the title and abstract by gpt-6-luna, p(non-human) 1.00).">mouse</span> | [Vera-Yunca_2025_cfu_2](drugs/drug_vancomycin/pd_Vera_Yunca_2025_cfu_2.md) | Bacterial load ← vancomycin · direct sigmoid Emax (Hill) effect | — | Vera-Yunca D et al., Model-based translation of the PKPD-rel…, The Journal of antimicrobia… (2025) | [10.1093/jac/dkaf140](https://doi.org/10.1093/jac/dkaf140) |
| <span class="pk-badge pk-badge--red">rejected</span> <span class="pk-badge pk-badge--species" title="Animal study (mouse), not measured in people (from an LLM reading of the title and abstract by gpt-6-luna, p(non-human) 1.00).">mouse</span> | [Vera-Yunca_2025_cfu](drugs/drug_vancomycin/pd_Vera_Yunca_2025_cfu.md) | Bacterial load ← vancomycin · direct sigmoid Emax (Hill) effect | ▶ model + simulator | Vera-Yunca D et al., Model-based translation of the PKPD-rel…, The Journal of antimicrobia… (2025) | [10.1093/jac/dkaf140](https://doi.org/10.1093/jac/dkaf140) |

## Pharmacogenomics (PGx)

| status | gene | affects | mechanism | detail | citation | doi |
|---|---|---|---|---|---|---|
| <span class="pk-badge pk-badge--green" title="the paper gives the effect of each phenotype (or genotype) on a named model parameter — a θ per category.">quantitative</span> <span class="pk-badge pk-badge--red" title="re-read by gpt-oss:120b (not confirmed, agreement 0.667). The first reading is what the record holds.">cross-check: disputed</span> | **unknown** | `Q22` · CL | metabolism | [Kurt_2026](drugs/drug_vancomycin/pgx_Kurt_2026_unknown_Q22.md) | Kurt İ et al., Evaluation of Vancomycin Therapeutic Dr…, European journal of clinica… (2026) | [10.1007/s00228-026-04103-w](https://doi.org/10.1007/s00228-026-04103-w) |

<details class="pk-legend"><summary>What the PGx badges mean — evidence, and whether a model runs</summary><table><tbody><tr><td><span class="pk-badge pk-badge--green">quantitative</span></td><td>the paper gives the effect of each phenotype (or genotype) on a named model parameter — a θ per category.</td></tr><tr><td><span class="pk-badge pk-badge--neutral">qualitative</span></td><td>the paper links the gene to the drug but states no effect size on a model parameter, so it changes no model.</td></tr><tr><td><span class="pk-badge pk-badge--neutral">guideline estimate</span></td><td>the effect comes from a CPIC / DPWG dosing guideline, not from this paper's numbers.</td></tr><tr><td><span class="pk-badge pk-badge--neutral">safety allele</span></td><td>a risk allele for an adverse reaction (an HLA type, G6PD deficiency …): it changes no PK/PD parameter.</td></tr><tr><td><span class="pk-badge pk-badge--orange">needs review</span></td><td>the extraction is incomplete or inconsistent.</td></tr><tr><td><span class="pk-badge pk-badge--red">rejected</span></td><td>not accepted.</td></tr><tr><td><span class="pk-badge pk-badge--green">▶ simulatable</span></td><td>the paper's popPK model runs per phenotype in the browser (Simulation tab); its PGx Modelica model is under Models.</td></tr><tr><td><span class="pk-badge pk-badge--neutral">model only</span></td><td>a PGx Modelica model exists but has no in-browser simulator.</td></tr></tbody></table></details>

<details class="legend">
<summary>What the PGx columns mean</summary>
<table><thead><tr><th>column</th><th>what it holds</th></tr></thead><tbody><tr><td><code>gene</code></td><td>the gene whose variants the record is about. One record per gene, so a paper reporting several genes appears on several rows.</td></tr><tr><td><code>affects</code></td><td>the PK or PD parameter the genotype SHIFTS, as an ontology Q-code plus its name — Q22 = clearance, Q27 = CL/F (apparent clearance), Q32 = Cmax, Q88 = AUC, Q40 = Fab, Q321 = EC50, Q322 = IC50, Q305 = kfm. The record's per-phenotype theta is a multiplier ON that parameter: a poor-metaboliser theta shifts this value, it does not supply one. Two values are NOT parameters — Q100 (NIL) is an association or risk finding with no parameter target, and `safety` is an adverse-reaction risk such as an HLA allele. A PA… id instead of a Q-code marks a record derived from a ClinPGx/PharmGKB guideline lookup rather than read out of the paper.</td></tr><tr><td><code>mechanism</code></td><td>how the gene acts: metabolism, transport, target, formation, safety_allele, or unknown.</td></tr><tr><td><code>detail</code></td><td>the paper stem, linking to the full record page.</td></tr><tr><th colspan="2" style="text-align:left;padding-top:10px">placeholders</th></tr><tr><td><code>not captured</code></td><td>the field is absent from the KB artifact — nothing was recorded. This is NOT the same as zero or empty: the value is unknown, not measured to be nothing.</td></tr><tr><td><code>—</code></td><td>deliberately not shown: the column does not apply to this row.</td></tr><tr><td><code>not verified</code></td><td>the record is not in an accepted state (see the badge and the note above the table); the numbers are shown as extracted, not endorsed.</td></tr></tbody></table>
</details>

## ADME sites

Where this drug is handled, from DrugBank's curated enzymes / transporters / carriers and the KB's PGx genes, mapped to tissue through the ADME gene table. Compare it with other drugs on the [Sites & interactions](sites?drugs=vancomycin) page (add drugs there; the set becomes a link).

| process | tissue | actors (role) | evidence |
|---|---|---|---|
| absorption | small intestine | <sub>named in DrugBank's ADME text</sub> | prose |
| distribution | blood | `ALB` substrate, `ORM1` substrate | DrugBank actor |
| metabolism | kidney | <sub>named in DrugBank's ADME text</sub> | prose |
| excretion | kidney | <sub>named in DrugBank's ADME text</sub> | prose |

<sub>Actors without a tissue in the table: UNKNOWN (metabolism).</sub>

<details class="legend">
<summary>Badge legend — what each badge means</summary>
<table><thead><tr><th>badge</th><th>what it means</th></tr></thead><tbody><tr><td><span class="pk-badge pk-badge--green">curated</span></td><td>hand-authored by a person — an exemplar, not an extraction.</td></tr><tr><td><span class="pk-badge pk-badge--green">extracted</span></td><td>the pipeline accepted the record: every closed-form check it could run passed.</td></tr><tr><td><span class="pk-badge pk-badge--green">reviewed — candidate</span></td><td>the reviewer ran the built model against the paper's own reported values and they agree — the best automatic verdict there is.</td></tr><tr><td><span class="pk-badge pk-badge--green">accepted (caveats)</span></td><td>the model replicates the paper, but an advisory check failed — the record page names the caveat under the badge and the drug page shows it under the status.</td></tr><tr><td><span class="pk-badge pk-badge--orange">needs review</span></td><td>extracted, then a check failed or a value looks implausible. The numbers are shown as read, not endorsed.</td></tr><tr><td><span class="pk-badge pk-badge--orange">built, not shipped</span></td><td>a model was built, but a core parameter fell back to a library default, so it is not shipped.</td></tr><tr><td><span class="pk-badge pk-badge--red">rejected</span></td><td>not accepted — the record is not a compartmental model, or nothing usable was extracted.</td></tr><tr><td><span class="pk-badge pk-badge--neutral">not modelled</span></td><td>pipeline state, not a judgement: no model has been built for this record yet (likewise `not simulated`).</td></tr><tr><td><span class="pk-badge pk-badge--stale">stale</span></td><td>the reviewer's verdict predates the latest re-run of the paper — treat the status as out of date, not as current.</td></tr><tr><td><span class="pk-badge pk-badge--green">cross-checked ✓</span></td><td>every independent reader agreed on every compared field. With more than one reader the badge counts them, e.g. 'cross-checked ✓ 2/2'.</td></tr><tr><td><span class="pk-badge pk-badge--orange">cross-check: partial</span></td><td>a reader differs on a non-structural field (a population label, a flag), or the readers do not all agree with each other.</td></tr><tr><td><span class="pk-badge pk-badge--red">cross-check: disputed</span></td><td>at least one reader differs on a structural parameter — a clearance, a volume, ka, a lag. The record still holds the FIRST reading; the disagreement is a signal for a reviewer, never an automatic correction.</td></tr><tr><td><span class="pk-badge pk-badge--species">rat</span></td><td>the data come from an animal (or in-vitro) study, not from people. The record, its model and its simulation are kept — they describe that species.</td></tr></tbody></table>
<p><small>The first badge is the record's <b>status</b> — what the pipeline and the reviewer concluded. A second badge, when present, is the <b>cross-check</b>: whether a model of another family, re-reading the same paper, extracted the same numbers. They are independent — a rejected record can be cross-checked, and a confirmed reading can still fail a plausibility check.</small></p>
</details>

## Coverage

- **PubMed hits:** 915 matched, 62 returned
- **screened:** 3  ·  **relevant:** 3
- **records:** 3  ·  extracted 3  ·  needs_review 0  ·  rejected 0  ·  stale 3
- **scholar-agent fallback query used:** not captured

## Full text wanted

_10 paper(s) judged relevant from the abstract, with no full text on disk — paywalled, or the resolver could not reach them. Follow the DOI, then save the PDF into `papers/` as `&lt;save as&gt;.pdf` and re-run the extraction._

| save as | citation | domain | score | DOI | PubMed | why wanted |
|---|---|---|---|---|---|---|
| `Avedissian_2022.pdf` | Avedissian SN et al., Vancomycin Pharmacokinetics in a Pregna…, Antimicrobial agents and ch… (2022) | popPK | 10 | [10.1128/aac.00056-22](https://doi.org/10.1128/aac.00056-22) | [35446134](https://pubmed.ncbi.nlm.nih.gov/35446134) | The study reports a population PK model for vancomycin in rats, but specific clearance and volume parameters are not explicitly listed in the text, only rate constants and concentrations. |
| `He_2021.pdf` | He CY et al., Population Pharmacokinetics and Dosing…, Antimicrobial agents and ch… (2021) | popPK | 10 | [10.1128/AAC.00897-21](https://doi.org/10.1128/AAC.00897-21) | [34339268](https://pubmed.ncbi.nlm.nih.gov/34339268) | The paper describes a population PK model for vancomycin in humans, but the specific numeric parameter values (CL, V, etc.) are not present in the provided abstract text. |
| `Oda_2024.pdf` | Oda K et al., Validation and development of populatio…, Journal of infection and ch… (2024) | popPK | 10 | [10.1016/j.jiac.2024.05.014](https://doi.org/10.1016/j.jiac.2024.05.014) | [38825002](https://pubmed.ncbi.nlm.nih.gov/38825002) | The paper describes a population pharmacokinetic model for vancomycin, but the specific numeric parameter values (CL, V, Q) are not present in the provided abstract text. |
| `Oda_2025.pdf` | Oda K et al., Development of Vancomycin Population Ph…, Journal of the Pediatric In… (2025) | popPK | 10 | [10.1093/jpids/piaf087](https://doi.org/10.1093/jpids/piaf087) | [40995929](https://pubmed.ncbi.nlm.nih.gov/40995929) | The paper describes a population pharmacokinetic model for vancomycin in pediatric patients, but the specific numeric parameter values (CL, V, etc.) are not present in the provided evidence. |
| `Lopez_2024.pdf` | Lopez ND et al., Vancomycin removal and pharmacokinetics…, Pharmacotherapy (2024) | popPK | 9 | [10.1002/phar.2885](https://doi.org/10.1002/phar.2885) | [37798109](https://pubmed.ncbi.nlm.nih.gov/37798109) | The study reports quantitative pharmacokinetic parameters (half-life, elimination rate constant, volume of distribution) for vancomycin in humans with specific numeric values provided in the abstract. |
| `del_2007.pdf` | del Mar Fernández de Gatta Garcia M et al., Pharmacokinetic/pharmacodynamic analysi…, Intensive care medicine (2007) | popPK | 9 | [10.1007/s00134-006-0470-5](https://doi.org/10.1007/s00134-006-0470-5) | [17165021](https://pubmed.ncbi.nlm.nih.gov/17165021) | The study reports population PK parameters for vancomycin in humans, but specific numeric values for clearance and volume are not explicitly listed in the provided abstract text. |
| `Giuliano_2010.pdf` | Giuliano C et al., Use of vancomycin pharmacokinetic-pharm…, Expert review of anti-infec… (2010) | pd | 5 | [10.1586/eri.09.123](https://doi.org/10.1586/eri.09.123) | [20014904](https://www.ncbi.nlm.nih.gov/pubmed/20014904) | metadata signals extractable PD data (PK-PD) |
| `Liu_2023.pdf` | Liu X et al., Differences in Pharmacokinetic/Pharmaco…, Pharmaceutical research (2023) | pd | 5 | [10.1007/s11095-022-03425-5](https://doi.org/10.1007/s11095-022-03425-5) | [36329373](https://www.ncbi.nlm.nih.gov/pubmed/36329373) | metadata signals extractable PD data (PK/PD) |
| `Zhang_2022.pdf` | Zhang Y et al., A Systematic Review of Population Pharm…, European journal of drug me… (2022) | pgx | 8 | [10.1007/s13318-021-00737-6](https://doi.org/10.1007/s13318-021-00737-6) | [34985725](https://www.ncbi.nlm.nih.gov/pubmed/34985725) | metadata signals extractable PGX data (SLCO1B1, PK/PD-context) |
| `Southall_2025.pdf` | Southall RL et al., Development, Verification, and Applicat…, The AAPS journal (2025) | pgx | 7 | [10.1208/s12248-025-01151-5](https://doi.org/10.1208/s12248-025-01151-5) | [41214361](https://www.ncbi.nlm.nih.gov/pubmed/41214361) | metadata signals extractable PGX data (CYP3A4, PK/PD-context) |

<sub>queue written 2026-10-04T18:41:45.935315+00:00</sub>

## Screened and excluded

| domain | paper | verdict | relevance | extractability | reason |
|---|---|---|---|---|---|
| PGx | Aschbacher_2012 | not_relevant | 0 | 0 | The paper analyzes bacterial genotypes (MRSA) and their susceptibility to vancomycin, not human pharmacogenomics affecting drug PK/PD. |
| popPK | Avedissian_2022 | relevant | 10 | 4 | The study reports a population PK model for vancomycin in rats, but specific clearance and volume parameters are not explicitly listed in the text, only rate constants and concentrations. |
| PGx | Baryakova_2020 | not_relevant | 0 | 0 | The paper focuses on the engineering of lysin proteins for antimicrobial activity, not on the pharmacogenomics of vancomycin. |
| PGx | Bellón_2022 | not_relevant | 0 | 0 | The paper reports an association between HLA-A*32:01 and the risk of an adverse drug reaction (DRESS), not a change in pharmacokinetic or pharmacodynamic parameters. |
| PGx | Bodeen_2026 | not_relevant | 0 | 0 | The paper is a clinical case report on ocular pyoderma gangrenosum and does not report any pharmacogenomic effects on vancomycin pharmacokinetics or pharmacodynamics. |
| PGx | Cheng_2024 | not_relevant | 0 | 0 | The paper investigates bacterial metabolic adaptations and resistance mechanisms in Staphylococcus aureus, not human pharmacogenomics or PK/PD parameters. |
| PGx | Chilambi_2020 | not_relevant | 0 | 0 | The paper studies the evolution of vancomycin-resistant bacteria (VRE) and does not report on human pharmacogenomics or PK/PD parameters of vancomycin. |
| PGx | Coppinger_2024 | not_relevant | 0 | 0 | The paper studies bacterial peptidoglycan biosynthesis and resistance mechanisms in Vibrio fischeri, not human pharmacogenomics or vancomycin PK/PD parameters. |
| PGx | Czock_2026 | not_relevant | 0 | 0 | The paper discusses drug-drug interactions and polypharmacy nephrotoxicity, not pharmacogenomic effects of gene variants on vancomycin PK/PD. |
| PGx | Douglas_2022 | not_relevant | 0 | 0 | The paper investigates the antibacterial activity of novel polyamines against S. aureus and does not report pharmacogenomic effects on the PK or PD of vancomycin. |
| PGx | Early_2016 | not_relevant | 0 | 0 | The study investigates a drug-drug interaction (metronidazole vs. vancomycin) on tacrolimus levels, not a pharmacogenomic effect on vancomycin. |
| popPK | Giuliano_2010 | irrelevant | 0 | 0 | no_text gate: only 96 chars of text extracted (&lt; 400) |
| PD | Giuliano_2010 | not_relevant | 1 | 0 | The provided text is only the title of a review article and does not contain the full text or any numeric PD parameters. |
| popPK | He_2021 | relevant | 10 | 2 | The paper describes a population PK model for vancomycin in humans, but the specific numeric parameter values (CL, V, etc.) are not present in the provided abstract text. |
| PGx | Hertzman_2021 | not_relevant | 0 | 0 | The paper discusses pharmacogenomic risk factors for hypersensitivity reactions (DRESS), not the effect of genetic variants on vancomycin pharmacokinetic or pharmacodynamic parameters. |
| PGx | Huang_2022 | not_relevant | 0 | 0 | The paper is a bioinformatics study on drug-induced liver injury mechanisms and does not report pharmacogenomic effects on vancomycin PK/PD parameters. |
| PGx | Iwamoto_2011 | not_relevant | 0 | 0 | The paper discusses tacrolimus, lansoprazole, and voriconazole, but does not report pharmacogenomic effects on vancomycin. |
| popPK | Jumah_2018 | irrelevant | 2 | 0 | The study reports pharmacodynamic exposure metrics (AUC/MIC) and clinical outcomes rather than quantitative pharmacokinetic disposition parameters (CL, V, Q, ka) for vancomycin. |
| PGx | Kampf_1999 | not_relevant | 0 | 0 | The paper investigates the bactericidal activity of hand disinfectants against VRE isolates, not the pharmacokinetics or pharmacodynamics of vancomycin in humans. |
| PGx | Katayama_2017 | not_relevant | 0 | 0 | The paper investigates bacterial genetics (SNPs in S. aureus) and phenotypic resistance (slow-VISA), not human pharmacogenomics or the effect of human gene variants on vancomycin PK/PD. |
| PGx | Kers_2018 | not_relevant | 0 | 0 | The paper investigates lantibiotic variants for C. difficile treatment and does not report pharmacogenomic effects on vancomycin PK/PD. |
| PGx | Kim_2016 | not_relevant | 0 | 0 | The paper describes the phenotypic characteristics of Staphylococcus aureus small-colony variants and their susceptibility to vancomycin, but does not report any human pharmacogenomic effects on vancomycin pharmacokinetics or pharmacodynamics. |
| PGx | Kussmann_2018 | not_relevant | 0 | 0 | The paper describes the emergence of bacterial resistance to dalbavancin, not a human pharmacogenomic effect on vancomycin PK/PD. |
| PGx | Lee_2022 | not_relevant | 0 | 0 | The paper reports on the association between HLA genotypes and the incidence of adverse drug reactions (toxicity), not on changes in pharmacokinetic or pharmacodynamic parameters. |
| PGx | Li_2020 | not_relevant | 0 | 0 | The paper reports the design and efficacy of a novel antimicrobial peptide (ID13) against S. aureus, with no mention of human gene variants or pharmacogenomic effects on vancomycin PK/PD. |
| popPK | Liu_2023 | irrelevant | 0 | 0 | no_text gate: only 91 chars of text extracted (&lt; 400) |
| PD | Liu_2023 | not_relevant | 0 | 0 | The paper focuses on Tedizolid, not vancomycin. |
| popPK | Liu_2024 | irrelevant | 2 | 0 | This is a literature review that summarizes existing studies but does not report original quantitative pharmacokinetic parameter values for vancomycin. |
| PGx | MOLANDER_1964 | not_relevant | 0 | 0 | The paper investigates the sensitivity of bacterial L-phase variants to vancomycin, which is a microbiological study, not a pharmacogenomic study of human PK/PD parameters. |
| PGx | M_2022 | not_relevant | 0 | 0 | The paper investigates the mechanism of red man syndrome (an adverse event) and drug targets, not the effect of genetic variants on vancomycin pharmacokinetics or pharmacodynamics. |
| popPK | Meagher_2005 | irrelevant | 0 | 0 | The paper describes the pharmacokinetics of tigecycline, not vancomycin. |
| PD | Meagher_2005 | not_relevant | 1 | 0 | The paper is a review of tigecycline (not vancomycin) and only qualitatively mentions that AUC/MIC predicts efficacy in animal models without providing numeric PD parameters or curves. |
| PGx | Morales_2026 | not_relevant | 0 | 0 | The paper is a scoping review mapping TDM research volume and characteristics in LMICs, not a study reporting specific pharmacogenomic effects on vancomycin PK/PD parameters. |
| popPK | Nham_2022 | irrelevant | 2 | 0 | The study reports PK/PD exposure metrics (AUC/MIC, trough) for clinical outcome prediction but does not report quantitative disposition parameters (CL, V, Q, ka) or a compartmental/population-PK model for vancomycin. |
| popPK | Oda_2024 | relevant | 10 | 2 | The paper describes a population pharmacokinetic model for vancomycin, but the specific numeric parameter values (CL, V, Q) are not present in the provided abstract text. |
| popPK | Oda_2025 | relevant | 10 | 0 | The paper describes a population pharmacokinetic model for vancomycin in pediatric patients, but the specific numeric parameter values (CL, V, etc.) are not present in the provided evidence. |
| PGx | Okado_2018 | not_relevant | 0 | 0 | The paper investigates bacterial resistance mechanisms (MRSA/hVISA) and in vitro susceptibility, not human pharmacogenomics or host gene variants affecting vancomycin PK/PD. |
| PGx | Pirmohamed_2019 | not_relevant | 0 | 0 | The paper focuses on HLA-associated immune-mediated adverse drug reactions (ADRs), not pharmacokinetic or pharmacodynamic parameters. |
| PGx | Radlinski_2017 | not_relevant | 0 | 0 | The paper investigates interspecies interactions between P. aeruginosa and S. aureus affecting antibiotic susceptibility, not human pharmacogenomics (gene variants affecting PK/PD). |
| popPK | Rao_2020 | irrelevant | 0 | 0 | The paper is a review of linezolid pharmacokinetics, not vancomycin. |
| PGx | Santa_2024 | not_relevant | 0 | 0 | The paper describes a biosensor for monitoring vancomycin levels but does not report any pharmacogenomic effects or gene variants influencing PK/PD parameters. |
| PGx | Seidl_2011 | not_relevant | 0 | 0 | The paper investigates the effect of a bacterial gene (agr) on vancomycin efficacy in an animal model, which is a microbiological resistance/virulence study, not a human pharmacogenomic study of host genetics affecting PK/PD. |
| PGx | Southall_2025 | not_relevant | 0 | 0 | The paper describes a physiologically based pharmacokinetic (PBPK) model for Chinese pediatrics and does not report any pharmacogenomic effects (gene variants) on vancomycin PK parameters. |
| PGx | Su_2023 | not_relevant | 0 | 0 | The paper reports bacterial antibiotic resistance to vancomycin, not a human pharmacogenomic effect on vancomycin PK or PD. |
| popPK | Tochikura_2024 | irrelevant | 2 | 0 | The study reports PK/PD outcomes (AUC/MIC ratios) rather than quantitative disposition parameters (CL, V, Q, ka) or a compartmental model for vancomycin. |
| PGx | Tsuji_2012 | not_relevant | 0 | 0 | The study investigates the pharmacodynamics of linezolid against bacterial genetic mutations, not the effect of human pharmacogenomics on vancomycin PK/PD. |
| popPK | Vera-Yunca_2025 | irrelevant | 2 | 0 | The study focuses on PKPD modeling of bacterial killing in mice and uses literature-based human PK models for simulation, but does not report original quantitative PK parameter estimates (CL, V, etc.) for vancomycin in the provided evidence. |
| PGx | Voulgaridou_2023 | not_relevant | 0 | 0 | The paper is a survey of TDM implementation in hospitals and does not report any pharmacogenomic effects on vancomycin PK/PD parameters. |
| popPK | Waineo_2015 | irrelevant | 2 | 0 | This is a review article discussing dosing strategies and PK/PD rationale without reporting original quantitative disposition parameters (CL, V, etc.) for vancomycin. |
| PD | Waineo_2015 | not_relevant | 2 | 1 | The paper is a literature review discussing PK/PD rationale and dosing strategies (AUC/MIC, Css) but does not report original data, fits, or specific numeric PD parameters (like Emax or EC50) for vancomycin. |
| PGx | Werth_2021 | not_relevant | 0 | 0 | The study investigates bacterial resistance mutations (walKR, etc.) induced by dalbavancin, not human pharmacogenomic variants affecting vancomycin PK/PD. |
| PGx | Yang_2014 | not_relevant | 0 | 0 | The paper reports a case of Stevens-Johnson syndrome (an adverse drug reaction) and identifies genetic variants associated with susceptibility, but it does not report any changes in pharmacokinetic or pharmacodynamic parameters of vancomycin. |
| PGx | Yukawa_2025 | not_relevant | 0 | 0 | The paper focuses on the clinical spectrum and antimicrobial resistance of Corynebacterium striatum, not on human pharmacogenomics or PK/PD parameters of vancomycin. |
| PGx | Zhang_2022 | not_relevant | 0 | 0 | The paper is a systematic review of methotrexate pharmacokinetics, not vancomycin. |
| PGx | Zhang_2024 | not_relevant | 0 | 0 | The paper characterizes a new antimicrobial peptide (AP138L-arg26) and compares its activity to vancomycin, but it does not report any pharmacogenomic effects (gene variants) on the PK or PD of vancomycin. |
| PGx | Zhao_2021 | not_relevant | 0 | 0 | The paper focuses on microbiology and culture medium optimization for isolating Lactobacillus, not on human pharmacogenomics or vancomycin PK/PD parameters. |
| PGx | Zhidkov_2024 | not_relevant | 0 | 0 | The paper evaluates the antibacterial and antitumor activities of a new compound (9-phenylfascaplysin) and does not report any pharmacogenomic effects on the pharmacokinetics or pharmacodynamics of vancomycin. |
| popPK | Zhu_2026 | irrelevant | 2 | 0 | The study is a retrospective PK/PD analysis reporting exposure metrics (AUC, Cmin) and clinical outcomes, but it does not report quantitative disposition parameters (CL, V, Q, ka) or a compartmental/population-PK model. |
| popPK | de_2004 | irrelevant | 2 | 0 | The paper is a review article that discusses pharmacokinetic concepts and administration regimens but does not report original quantitative parameter values (CL, V, etc.) in the provided text. |
| popPK | del_2007 | relevant | 9 | 2 | The study reports population PK parameters for vancomycin in humans, but specific numeric values for clearance and volume are not explicitly listed in the provided abstract text. |

---
<sub>Generated by `docs.py` (scholarv2) · newest extraction 2026-10-04 18:41 UTC</sub>
